5 results found.

Ovarian Clear Cell Cystadenocarcinoma, Ovarian Endometrioid Adeno Clinical Trial using veliparib; pegylated liposomal doxorubicin hydrochloride; carboplatin; bevacizumab; laboratory biomarker analysis

National Cancer Institute (NCI) - Recruiting 18 years or older.
- A Phase I Trial of Pegylated Liposomal Doxorubicin (PLD), Carboplatin, and NCI Supplied Veliparib (ABT-888), and NCI Supplied Bevacizumab in Recurrent Platinum Sensitive Ovarian, Primary Peritoneal and Fallopian Tube Cancer.
veliparib; pegylated liposomal doxorubicin hydrochloride; carboplatin; bevacizumab; laboratory biomarker analysis

Brenner Tumor, Ovarian Clear Cell Cystadenocarcinoma, Ovarian End Clinical Trial using behavioral dietary intervention; exercise intervention; counseling intervention; educational intervention; compliance monitoring; questionnaire administration; quality-of-life assessment; laboratory biomarker analysis

Gynecologic Oncology Group - Recruiting 18 years or older.
- Can Diet and Physical Activity Modulate Ovarian, Fallopian Tube and Primary Peritoneal Cancer Progression-Free Survival?.
behavioral dietary intervention; exercise intervention; counseling intervention; educational intervention; compliance monitoring; questionnaire administration; quality-of-life assessment; laboratory biomarker analysis

Brenner Tumor, Ovarian Clear Cell Cystadenocarcinoma, Ovarian End Clinical Trial using elesclomol sodium; paclitaxel

Gynecologic Oncology Group - Recruiting 18 years or older.
- A PHASE II EVALUATION OF ELESCLOMOL SODIUM AND WEEKLY PACLITAXEL IN THE TREATMENT OF RECURRENT OR PERSISTENT PLATINUM-RESISTANT OVARIAN, FALLOPIAN TUBE OR PRIMARY PERITONEAL CANCER.
elesclomol sodium; paclitaxel

Brenner Tumor, Ovarian Clear Cell Cystadenocarcinoma, Ovarian End Clinical Trial using paclitaxel poliglumex; clinical observation; paclitaxel

Gynecologic Oncology Group - Recruiting N/A or older.
- A Randomized Phase III Trial of Maintenance Chemotherapy Comparing 12, Monthly Cycles of Single Agent Paclitaxel or CT-2103 (IND #70177), Versus No Treatment Until Documented Relapse in Women With Advanced Ovarian, Primary Peritoneal or Fallopian Tube Cancer Who Achieve a Complete Clinical Response to Primary Platinum/Taxane Chemotherapy.
paclitaxel poliglumex; clinical observation; paclitaxel

Brenner Tumor, Ovarian Clear Cell Cystadenocarcinoma, Ovarian End Clinical Trial using bortezomib; carboplatin; pharmacological study

National Cancer Institute (NCI) - Recruiting 18 years or older.
- A PHASE I PHARMACOKINETIC STUDY OF INTRAPERITONEAL CTEP-SUPPLIED AGENT BORTEZOMIB (PS-341, NSC 681239, IND# 58443) AND CARBOPLATIN (NSC# 241240) IN PATIENTS WITH PERSISTENT OR RECURRENT OVARIAN, FALLOPIAN TUBE, OR PRIMARY PERITONEAL CANCER.
bortezomib; carboplatin; pharmacological study